Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 1974-1981

  Kaminski, M S ^a   Zasadny, K R ^a   Francis, I R ^a   Fenner, M C ^a   Ross, C W ^a   Milik, A W ^a   Estes, J ^a   Tuck, M ^a   Regan, D ^a   Fisher, S ^a   Glenn, S D ^a   Wahl, R L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; IODINE 131; MONOCLONAL ANTIBODY CD20; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; ISOTOPE LABELING; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT FAILURE;

EID: 8944248819     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.1974     Document Type: Article

References (28)

1. Fisher RI, Gaynor E, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
2. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993
3. Gallagher CJ, Gregory SM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
4. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993
5. 131I-anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993
6. Stashenko P, Nadler LM, Hardy R, et al: Characterization of a human B lymphocyte specific antigen. J Immunol 125:1678-1685, 1980
7. Fraker PJ, Speck JS Jr: Protein and cell membrane iodinations with a sparingly soluble chloramide, 1, 3, 4, 6-tetrachloro-3a, 6a-diphenylglycouracil. Biochem Biophy Res Commun 80:849-857, 1978
8. Wahl RL, Wissing JR, del Rosario R, et al: Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 31:84-89, 1990
9. Kaminski MS, Fig LM, Zasadny KR, et al: Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10:1696-1711, 1992
10. International Commission on Radiological Protection: Report of the Task Group on Reference Man. Oxford, United Kingdom, Pergamon, 1975
11. Ellet W, Humes R: Absorbed fractions for small volumes containing photon-emitting radioactivity. NM/MIRD pamphlet no. 8. Society of Nuclear Medicine, New York, NY, 1971
12. Dillman LT, Von der Lage F: Radionuclide decay scheme and nuclear parameters for use in radiation-dose estimation. NM/ MIRD pamphlet no. 10. Society of Nuclear Medicine, New York, NY, 1975
13. Snyder W, Ford M, Warner G, et al: "S", absorbed dose per unit cumulated activity for selected radionuclides and organs. NM/ MIRD pamphlet no. 11. Society of Nuclear Medicine, New York, NY, 1975
14. Watson E, Stabin M, Wesley E: Mirdose (ed 2). Oak Ridge, TN, Associated Universities, 1984
15. Armitage JO, Dick FR, Corder MP: Diffuse histiocytic lymphoma after histologic conversion: A poor prognostic variant. Cancer Treat Rep 65:413-418, 1981
16. Ostrow SS, Diggs CH, Sutherland JC, et al: Nodular poorly differentiated lymphocytic lymphoma: Changes in histology and survival. Cancer Treat Rep 65:929-933, 1981
17. Goldenberg DM, Horowitz JA, Sharkey RM, et al: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548-564, 1991
18. 131I Lym-1 monoclonal antibodies. Int J Cancer 40:96-101, 1988 (suppl 6)
19. 131I Lym-1 monoclonal antibody. Antibod Immunoconjugates Radiopharmaceut 1:17-33, 1988
20. 131I Lym-1. Cancer Res 50:1014s-1016s, 1990 (suppl)
21. Parker BA, Vassos AB, Halpern SE, et al: Radioimmunotherapy of human B-cell lymphoma with 90-Y-conjugated antiidiotype monoclonal antibody. Cancer Res 50:1022s-1028s, 1990 (suppl)
22. Czuczman MS, Straus DJ, Divgi CR, et al: Phase I doseescalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 11:2021-2028, 1993
23. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
24. Press OW, Eary JF, Applebaum FR, et al: Phase II trial of 131-I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
25. Buchsbaum DJ, Wahl RL, Normolle DP, et al: Therapy with unlabeled and 131-I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 52:6476-6481, 1992
26. Bast RC, Ritz J, Lipton JM, et al: Elimination of leukemia cells from human bone marrow using monoclonal antibodies and complement. Cancer Res 43:1389-1396, 1983
27. Tedder TF, Boyd AW, Freedman AS, et al: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973-979, 1985
28. Tedder TF, Forsgren A, Boyd AW, et al: Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of B lymphocytes. Eur J Immunol 16:881-887, 1986